{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kieburtz K"],"funding":["NIA NIH HHS"],"pagination":["154-60"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4134015"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["67(2)"],"pubmed_abstract":["<h4>Objectives</h4>To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.<h4>Design</h4>Double-blind, randomized, placebo-controlled trial.<h4>Setting</h4>Multicenter outpatient trial.<h4>Participants</h4>Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.<h4>Intervention</h4>Latrepirdine, 20 mg 3 times daily (n = 46), or matching placebo (n = 45) for a 90-day treatment period.<h4>Main outcome measures</h4>The primary outcome variable was tolerability, defined as the ability to complete the study at the assigned drug dosage. Secondary outcome variables included score changes from baseline to day 90 on the Unified Huntington"],"journal":["Archives of neurology"],"pubmed_title":["A randomized, placebo-controlled trial of latrepirdine in Huntington disease."],"pmcid":["PMC4134015"],"funding_grant_id":["R01 AG031189"],"pubmed_authors":["Elliott K","Seitz W","Goldstein J","Nickerson C","Porter R","Cartwright MS","Kostyk S","Moskowitz C","Wright B","Agarwal A","Tempkin T","Pourfar M","Kieburtz K","Mozer E","Molho E","Corey-Bloom J","Evans S","Matthews M","Hunt V","Deuel LM","Guzijan M","Bronson M","Dimebon in Subjects with Huntington Disease (DIMOND) Investigators of the Huntington Study Group","Ayan J","Bender A","Feigin A","Jaglin J","Cudkowicz M","Sweany M","McDermott MP","Wheelock V","Dorsey ER","Factor S","O'Neill C","Wojcieszek J","Rabinowitz K","McCall M","McNees A","Hersch S","Wood-Siverio C","Geschwind MD","Welsh C","Shannon K","Hung D","Voss TS","Altin L","Roy J","Yoritomo N","Stanley M","Colcher A","Hodgeman K","Frucht S","Harrison J","Walker F","Mason S","Sanchez-Ramos J","Kayson E","Huntington Disease Study Group DIMOND Investigators","Ravina B","Hickey C","Weber J","Seely L","Selby B","Leventhal C","Belden J","Rosenblatt A","Orme C","Noonberg S","Watts A","Lessig S","Tatum R","Seward A","Barker RA"],"additional_accession":[]},"is_claimable":false,"name":"A randomized, placebo-controlled trial of latrepirdine in Huntington disease.","description":"<h4>Objectives</h4>To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.<h4>Design</h4>Double-blind, randomized, placebo-controlled trial.<h4>Setting</h4>Multicenter outpatient trial.<h4>Participants</h4>Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.<h4>Intervention</h4>Latrepirdine, 20 mg 3 times daily (n = 46), or matching placebo (n = 45) for a 90-day treatment period.<h4>Main outcome measures</h4>The primary outcome variable was tolerability, defined as the ability to complete the study at the assigned drug dosage. Secondary outcome variables included score changes from baseline to day 90 on the Unified Huntington","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Feb","modification":"2025-05-29T21:30:37.97Z","creation":"2019-03-27T01:34:06Z"},"accession":"S-EPMC4134015","cross_references":{"pubmed":["20142523"],"doi":["10.1001/archneurol.2009.334"]}}